Press Releases

The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.

Johnson & Johnson Wins U.S. Food and Drug Administration Approval for TECVAYLI + DARZALEX FASPRO in Relapsed/Refractory Multiple Myeloma

Johnson & Johnson a worldwide leader in multiple myeloma therapies, announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.1 TECVAYLI® and DARZALEX FASPRO® work synergistically to prime and activate the immune system to eradicate myeloma cells that express the BCMA protein.

BD Advances Iliac Artery Treatment Across the European Union

BD a leading global medical technology company, announced it has obtained CE Marking for the Revello™ Vascular Covered Stent, a next-generation endovascular solution for the treatment of atherosclerotic lesions in the common and external iliac arteries.

Avenacy announces the launch of Diphenhydramine Hydrochloride Injection, USP, in the U.S. market

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced the launch of Diphenhydramine Hydrochloride Injection, USP in the United States.

Otsuka Medical Devices/Otsuka Pharmaceutical announces the commercial launch of the Paradise Ultrasound Renal Denervation System in Japan

Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective March 1. Following the inception of insurance coverage, Otsuka Medical Devices has commenced sales of the system on March 2 and will conduct co-promotion with Otsuka Pharmaceutical.

Pharma Service Provider Vetter Pharma Building New Manufacturing Site in Germany

Vetter, one of the world's leading pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany.

Pulsenmore Announces First Commercial Engagement with a Leading US Based Medical Center

Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the United States, following receipt of FDA approval for its home pregnancy ultrasound product.

The International Zinc Association Forms a Partnership with Pharmanova to Save Children in Zambia

Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia.

FDA Clears SurGenTec®’s ION-C™ Facet Fixation System to Support Fusion While Preserving Alignment

SurGenTec®, a medical device innovation company focused on advancing treatment options for orthopedic and spine surgery, announced FDA clearance of its ION-C™ Facet Fixation System.

A Los Angeles Neurology Clinic Emerges as a Clinical Home for CBD IV Therapy

PICO IV, a leading innovator in sterile cannabidiol (CBD) solutions, announced a closely coordinated clinical collaboration with BrainThrive, PC, a neurology and diagnostic testing center in Westlake Village, California.

Aptar Nasal Vaccine Delivery Solutions Used in CastleVax Phase II Intranasal COVID-19 Vaccine Trial

AptarGroup, Inc. a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, announced that its innovative nasal vaccine delivery solutions, LuerVax® and Spray Divider™, are being utilized in CastleVax’s Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate.

Latest Press Releases